华蟾素联合帕米磷酸二钠治疗脊柱骨转移癌性疼痛的临床价值研究

Clinical value of cinobufacini combined with pamidronate in the treatment of spinal metastatic cancer pain

目的探讨华蟾素胶囊联合帕米磷酸二钠在治疗脊柱骨转移癌性疼痛方面的临床价值及安全性。方法将本中心收住的70例恶性肿瘤伴脊柱骨转移患者随机分为治疗组与对照组各35例,对照组单独采用帕米磷酸二钠治疗,治疗组采用帕米磷酸二钠联合华蟾素胶囊,评估比较两组患者后期疼痛评分(NRS评分)、疼痛程度、降低止痛药物用量及相关不良反应等指标。结果治疗组患者经联合治疗后,NRS评分显著低于对照组(2.11±0.85 vs 4.71±1.86;P<0.05),治疗组患者疼痛缓解总有效率显著优于对照组(65.71%vs 40%;P<0.05),治疗组患者的阿片类药物用量显著少于对照组(P<0.05),而两组不良反应无显著性差异(P>0.05)。结论华蟾素胶囊联合帕米磷酸二钠在辅助治疗恶性肿瘤伴脊柱骨转移癌性疼痛方面疗效显著,可以显著减少阿片类药物的用量,且不增加相关临床不良反应。

Objective To evaluate the clinical value and safety of cinobufacini capsule combined with pamidronate in the treatment of spinal metastatic cancer pain.Methods A total of 70 malignant tumor patients with spinal bone metastases were randomly divided into treatment group and control group,with 35 cases in each group.The control group was treated with pamidronate alone,while the treatment group was treated with pamidronate injection combined with cinobufagin capsule.The NRS score,pain degree,reduced dosage of analgesics and adverse reactions of the two groups were evaluated and compared.Results After combined treatment,the NRS score of the treatment group was significantly lower than that of the control group[(2.11±0.85)vs(4.71±1.86),P<0.05],and the pain relief effect of the treatment group was significantly better than that of the control group(65.71%vs 40%,P<0.05).The dosage of opioid analgesics in the treatment group was significantly less than that in the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion Cinobufacini capsule combined with pamidronate is effective in adjuvant treatment of cancer pain caused by malignant tumor with spinal bone metastasis,which can significantly reduce the dosage of opioid analgesics without increasing the related clinical adverse reactions.